Phase III data backs Acacia Pharma's Baremsis in post-operative nausea and vomiting

UK-based Acacia Pharma has announced positive top-line results from a pivotal Phase III study of Baremsis (amisulpride injection) as a treatment for established post-operative nausea and vomiting (PONV).

The supportive care company, which is developing product opportunities for post-surgical and cancer patients for the US and international markets, has previously shown the efficacy of Baremsis both alone and in combination with standard anti-emetics in pivotal Phase III prophylaxis studies, so this trial offers further proof of its effectiveness.

Julian Gilbert, Acacia Pharma’s chief executive, said: “We are delighted with these data demonstrating that Baremsis is safe and effective at treating patients suffering PONV after surgery. It confirms our confidence in the dopamine antiemetic mechanism of action, and that Baremsis is effective at treating, as well as preventing, PONV.